Immuron Limited Operating Income 2011-2026 | IMRN

Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.

Formula

Operating profit = Revenue – Operating expenses

Features of the metric

Evaluates business efficiency
Shows how well the company controls its production and administrative costs.
Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies.
Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.

If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.

Annual Operating Income Immuron Limited

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-2.87 M	-8.38 M	-2.91 M	-4.63 M	-2.99 M	-6.72 M	-	-	-	-	-	-

All numbers in AUD currency

Indicator range from annual reports

Maximum	Minimum	Average
-2.87 M	-8.38 M	-4.75 M

Operating Income of other stocks in the Biotechnology industry

Issuer	Operating Income	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	-508 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	-88.1 M	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	15.1 B	$ 209.63	-0.71 %	$ 371 B	USA
Verastem VSTM	-170 M	$ 4.99	-5.77 %	$ 346 M	USA
VistaGen Therapeutics VTGN	-56 M	$ 0.57	-5.85 %	$ 17.6 M	USA
Aeterna Zentaris AEZS	-8.67 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	-24 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	-210 M	-	-	$ 1.01 B	USA
AIkido Pharma AIKI	-11.5 M	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	-86.8 M	-	0.23 %	$ 488 M	USA
Akero Therapeutics AKRO	-285 M	-	-	$ 3.67 B	USA
Genfit SA GNFT	31.8 M	-	2.54 %	$ 160 B	France
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Voyager Therapeutics VYGR	-132 M	$ 3.96	-4.24 %	$ 232 M	USA
Biophytis SA BPTS	-26.8 M	-	-13.47 %	$ 169 M	France
Aileron Therapeutics ALRN	-50.6 M	-	10.36 %	$ 9.8 M	USA
Aptinyx APTX	-62.6 M	-	-39.0 %	$ 4.57 M	USA
Midatech Pharma plc MTP	-7 M	-	-18.52 %	$ 27.3 M	Britain
Arena Pharmaceuticals ARNA	-624 M	-	-6.81 %	$ 3.04 B	USA
Applied Genetic Technologies Corporation AGTC	-17.7 M	-	-	$ 26.5 M	USA
Avenue Therapeutics ATXI	-11.3 M	-	-52.27 %	$ 4.45 M	USA
Ayala Pharmaceuticals AYLA	-37.5 M	-	-	$ 7.46 M	Israel
Acorda Therapeutics ACOR	-265 M	-	-24.86 %	$ 820 K	USA
bluebird bio BLUE	-244 M	-	-	$ 546 M	USA
Acasti Pharma ACST	-16.7 M	-	4.01 %	$ 150 M	Canada
Avid Bioservices CDMO	-18.7 M	-	-	$ 789 M	USA
Adverum Biotechnologies ADVM	-139 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	-24.6 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	-36.3 M	-	-9.65 %	$ 45.9 M	USA
Adaptive Biotechnologies Corporation ADPT	-57.1 M	$ 12.36	-11.46 %	$ 1.88 B	USA
Wave Life Sciences Ltd. WVE	-215 M	$ 6.39	3.06 %	$ 1.08 B	Singapore
Xenetic Biosciences XBIO	-2.83 M	$ 2.78	-0.71 %	$ 4.73 M	USA
BeiGene, Ltd. BGNE	447 M	-	0.49 %	$ 251 B	Cayman-islands
XBiotech XBIT	-55.7 M	$ 2.27	-1.73 %	$ 69.2 M	USA
Xenon Pharmaceuticals XENE	-279 M	$ 54.44	-1.96 %	$ 4.24 B	Canada
Xeris Pharmaceuticals XERS	24.9 M	$ 5.41	-2.87 %	$ 868 M	USA
X4 Pharmaceuticals XFOR	-86.9 M	$ 4.07	-5.57 %	$ 172 M	USA
Xencor XNCR	-178 M	$ 11.4	-7.43 %	$ 846 M	USA
XOMA Corporation XOMA	11.4 M	$ 29.93	-1.97 %	$ 362 M	USA
22nd Century Group XXII	-11.6 M	$ 2.41	-18.03 %	$ 444 K	USA
BioDelivery Sciences International BDSI	37.1 M	-	-4.8 %	$ 255 M	USA
Cara Therapeutics CARA	-121 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	-130 M	-	-	$ 3.74 B	USA
Enlivex Therapeutics Ltd. ENLV	-15.9 M	$ 1.06	-2.75 %	$ 21.7 M	Israel
Enochian Biosciences ENOB	-189 M	-	-	$ 40.5 M	USA